The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of<i>Pneumocystis</i>pneumonia in patients with rheumatic diseases

Abstract

Patients who received a reduced SMX/TMP dose did not have PCP and had a lower frequency of AEs. A reduction in SMX/TMP for PCP prophylaxis is effective and safe in patients with rheumatic disease.